Blue Crest Capital Management LTD Immuno Gen, Inc. Transaction History

Blue Crest Capital Management LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $42,366 - $64,694	-19,084 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $34,351 - $62,977	19,084 New	19,084 $41,000
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $57,899 - $90,446	-11,420 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $61,668 - $96,727	11,420	11,420 $87,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.